{"id":2074,"date":"2004-11-01T12:06:00","date_gmt":"2004-11-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/moegliche-uaw-von-pioglitazon-und-bosentan"},"modified":"2004-11-01T12:06:00","modified_gmt":"2004-11-01T11:06:00","slug":"moegliche-uaw-von-pioglitazon-und-bosentan","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/moegliche-uaw-von-pioglitazon-und-bosentan","title":{"rendered":"M\u00f6gliche UAW von Pioglitazon und Bosentan"},"content":{"rendered":"<p>Wir berichten erneut \u00fcber \u201eDrug points\u201d im British Medical Journal: E. Farley-Hills et al. aus Indien (1) berichten \u00fcber einen 63-j\u00e4hrigen Diabetiker ohne Alkohol- und Leber-Anamnese, der drei Monate nach Umsetzen von dem Sulfonylharnstoff Gliclazid (Diamicron Uno\u00ae) auf das Thiazolidindion Pioglitazon (Actos\u00ae; s.a. 2) mit einem Ikterus bei stark erh\u00f6hten Transaminasen und Gamma-GT sowie einem [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir berichten erneut \u00fcber \u201eDrug points\u201d im British Medical Journal: E. Farley-Hills et al. aus Indien (1) berichten \u00fcber einen 63-j\u00e4hrigen Diabetiker ohne Alkohol- und Leber-Anamnese, der drei Monate nach Umsetzen von dem Sulfonylharnstoff Gliclazid (Diamicron Uno\u00ae) auf das Thiazolidindion Pioglitazon (Actos\u00ae; s.a. 2) mit einem Ikterus bei stark erh\u00f6hten Transaminasen und Gamma-GT sowie einem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1828,4258,157,1332,3709],"class_list":["post-2074","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-bosentan","tag-leberfibrose","tag-orale-antidiabetika","tag-pioglitazon","tag-vaskulitis"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2074"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2074\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}